Juvenile Idiopathic Arthritis Associated Uveitis. Modern Therapy Approaches: Narrative Review
https://doi.org/10.15690/vsp.v24i3.2910
Abstract
Juvenile idiopathic arthritis (JIA) associated uveitis is the most common extra-articular manifestation of JIA. Nowadays, unified approach for the management of this condition has been developed despite all the difficulties in diagnosis. It allows to avoid many long-term complications and improves patients’ quality of life. Rapid development of pharmacotherapy (including appearance of new immunosuppressive and genetically engineered biologic drugs) expands the therapeutic methods and increases the chances in achieving sustained remission. However, still there are many questions regarding genetically engineered biologic drugs safety, optimal time to treatment cessation, and long-term follow-up in patients with JIA. This review summarizes and analyzes modern data regarding treatment approaches, therapy efficacy and safety, and perspectives for managing patients with uveitis and JIA.
About the Authors
Alexandr A. Yakovlev
Saint Petersburg State Pediatric Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Saint Petersburg
Disclosure of interest:
None
Tatiana N. Nikitina
Saint Petersburg State Pediatric Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Saint Petersburg
Disclosure of interest:
None
Mikhail M. Kostik
Saint Petersburg State Pediatric Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Saint Petersburg
Disclosure of interest:
None
References
1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778. doi: https://doi.org/10.1016/S0140-6736(07)60363-8
2. Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322. doi: https://doi.org/10.1016/j.clim.2019.108322
3. Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken). 2019;71(6):703–716. doi: https://doi.org/10.1002/acr.23871
4. Chen WD, Wu CH, Wu PY, et al. Taiwan ocular inflammation society consensus recommendations for the management of juvenile idiopathic arthritis-associated uveitis. J Formos Med Assoc. 2024;123(12):1218–1227. doi: https://doi.org/10.1016/j.jfma.2024.02.010
5. Foeldvari I, Maccora I, Petrushkin H, et al. New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Chronic Anterior Uveitis. Arthritis Care Res (Hoboken). 2023;75(5):975–982. doi: https://doi.org/10.1002/acr.24963
6. Uveity neinfektsionnye: Clinical guidelines. Association of ophthalmologists, Society of ophthalmologists of Russia. In: Rubrikator klinicheskikh rekomendatsii: Official website. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/preview-cr/787_1. Ссылка активна на 03.03.2025.
7. Uveity, assotsiirovannye s yuvenil’nym idiopaticheskim artritom: Clinical guidelines. Association of ophthalmologists. Ministry of Health of the Russian Federation; 2017. (In Russ). Доступно по: https://eyepress.ru/sbornik.aspx?668. Ссылка активна на 03.03.2025.
8. Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107–1117. doi: https://doi.org/10.1136/annrheumdis-2018-213131
9. Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015;35(5):777–785. doi: https://doi.org/10.1007/s00296-015-3231-3
10. Neves LM, Haefeli LM, Hopker LM, et al. Monitoring and Treatment of Juvenile Idiopathic Arthritis-associated Uveitis: Brazilian Evidence-based Practice Guidelines. Ocul Immunol Inflamm. 2022;30(6):1384–1398. doi: https://doi.org/10.1080/09273948.2021.1876886
11. Kothari S, Foster CS, Pistilli M, et al. The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis. Ophthalmology. 2015;122(10):1987–2001. doi: https://doi.org/10.1016/j.ophtha.2015.06.041
12. Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2019;49(1):43–55. doi: https://doi.org/10.1016/j.semarthrit.2018.11.004
13. Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436–1441. doi: https://doi.org/10.1016/j.ophtha.2009.12.003
14. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516. doi: https://doi.org/10.1016/j.ajo.2005.03.057
15. Roesel M, Gutfleisch M, Heinz C, et al. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res. 2009;42(2):81–86. doi: https://doi.org/10.1159/000220600
16. Gaudio PA. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm. 2004;12(3):169–192. doi: https://doi.org/10.1080/092739490500192
17. Wakefield D, McCluskey P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol. 1986;104(6):847–851. doi: https://doi.org/10.1001/archopht.1986.01050180081035
18. Pichi F, Nucci P, Baynes K, et al. Sustained-release dexamethasone intravitreal implant in juvenile idiopathic arthritis-related uveitis. Int Ophthalmol. 2017;37(1):221–228. doi: https://doi.org/10.1007/s10792-016-0265-9
19. Cordero-Coma M, Garzo I, Calleja S, et al. Preoperative cataract surgery use of an intravitreal dexamethasone implant (Ozurdex) in a patient with juvenile idiopathic arthritis and chronic anterior uveitis. J AAPOS. 2013;17(6):632–634. doi: https://doi.org/10.1016/j.jaapos.2013.07.014
20. Carlsson E, Beresford MW, Ramanan AV, et al. Juvenile Idiopathic Arthritis Associated Uveitis. Children (Basel). 2021;8(8):646. doi: https://doi.org/10.3390/children8080646
21. Kim L, Li A, Angeles-Han S, et al. Update on the management of uveitis in children: an overview for the clinician. Expert Rev Ophthalmol. 2019;14(4-5):211–218. doi: https://doi.org/10.1080/17469899.2019.1663731
22. Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52(5):825–831. doi: https://doi.org/10.1093/rheumatology/kes186
23. Wieringa WG, Armbrust W, Legger GE, Los LI. Efficacy of High-Dose Methotrexate in Pediatric Non-Infectious Uveitis. Ocul Immunol Inflamm. 2019;27(8):1305–1313. doi: https://doi.org/10.1080/09273948.2018.1529800
24. Zu Hoerste MM, Walscheid K, Tappeiner C, et al. The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol. 2018;256(10):1985–1992. doi: https://doi.org/10.1007/s00417-018-4082-x
25. Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014;32(4):563–571.
26. Tuková J, Chládek J, Nemcová D, et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2009;27(6):1047–1053.
27. van Roon EN, van de Laar MA. Methotrexate bioavailability. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S27–S32.
28. van Straalen JW, Akay G, Kouwenberg CV, et al. Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis. RMD Open. 2023;9(2):e003010. doi: https://doi.org/10.1136/rmdopen-2023-003010
29. Tirelli F, Zannin ME, Vittadello F, et al. Methotrexate Monotherapy in Juvenile Idiopathic Arthritis Associated Uveitis: Myth or Reality? Ocul Immunol Inflamm. 2022;30(7-8):1763–1767. doi: https://doi.org/10.1080/09273948.2021.1951303
30. Kostik MM, Gaidar EV, Hynnes AY, et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol. 2016;34(4):714–718.
31. Papadopoulou C, Kostik M, Böhm M, et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr. 2013;163(3):879–884. doi: https://doi.org/10.1016/j.jpeds.2013.03.047
32. Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95(2):209–213. doi: https://doi.org/10.1136/bjo.2009.173542
33. Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for Ocular Inflammatory Diseases. Am J Ophthalmol. 2009;148(4): 500–509.e2. doi: https://doi.org/10.1016/j.ajo.2009.05.008
34. Savolainen HA, Kautiainen H, Isomäki H, et al. Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol. 1997;24(12):2444–2450.
35. Maleki A, Anesi SD, Look-Why S, et al. Pediatric uveitis: A comprehensive review. Surv Ophthalmol. 2022;67(2):510–529. doi: https://doi.org/10.1016/j.survophthal.2021.06.006
36. Chang PY, Giuliari GP, Shaikh M, et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond). 2011;25(4):427–435. doi: https://doi.org/10.1038/eye.2011.23
37. Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91(2): 180–184. doi: https://doi.org/10.1136/bjo.2006.094698
38. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115(8):1416–1421.e1. doi: https://doi.org/10.1016/j.ophtha.2007.12.011
39. Cantarini L, Simonini G, Frediani B, et al. Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert Opin Investig Drugs. 2012;21(1):1–6. doi: https://doi.org/10.1517/13543784.2012.636350
40. Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. JAMA. 2019;322(10):936–945. doi: https://doi.org/10.1001/jama.2019.12618
41. Reddy AK, Miller DC, Sura AA, et al. Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial. J Ophthalmic Inflamm Infect. 2023;13(1):29. doi: https://doi.org/10.1186/s12348-023-00350-5
42. Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121(10):1863–1870. doi: https://doi.org/10.1016/j.ophtha.2014.04.023
43. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–734. doi: https://doi.org/10.1002/acr.23870
44. Aggarwal A, Misra DP. Enthesitis-related arthritis. Clin Rheumatol. 2015;34(11):1839–1846. doi: https://doi.org/10.1007/s10067-015-3029-4
45. Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003;30(6):1277–1279.
46. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000;14(Pt 3A):340–343. doi: https://doi.org/10.1038/eye.2000.84
47. Huang JL, Hung IJ, Hsieh KH. Sulphasalazine therapy in chronic uveitis of children with chronic arthritis. Asian Pac J Allergy Immunol. 1997;15(2):71–75.
48. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med. 1992;326(25):1654–1660. doi: https://doi.org/10.1056/NEJM199206183262502
49. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112(2): 138–146. doi: https://doi.org/10.1016/s0002-9394(14)76692-9
50. Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond). 2009;23(5): 1192–1198. doi: https://doi.org/10.1038/eye.2008.174
51. Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114(5):1000–1006. doi: https://doi.org/10.1016/j.ophtha.2007.01.026
52. Dini G, Dell’Isola GB, Beccasio A, et al. Biologic therapies for juvenile idiopathic arthritis-associated uveitis. Front Ophthalmol (Lausanne). 2022;2:954901. doi: https://doi.org/10.3389/fopht.2022.954901
53. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251–255. doi: https://doi.org/10.1159/000055677
54. Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, et al. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004;20(2):155–157. doi: https://doi.org/10.1185/030079903125002847
55. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617–637. doi: https://doi.org/10.1016/j.preteyeres.2004.06.005
56. Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994;35(11):3884–3889.
57. Sen ES, Ramanan AV. New age of biological therapies in paediatric rheumatology. Arch Dis Child. 2014;99(7):679–685. doi: https://doi.org/10.1136/archdischild-2013-304396
58. Gerriets V, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available online: https://www.ncbi.nlm.nih.gov/ books/NBK482425. Accessed on Marth 05, 2023.
59. Foeldvari I, Becker I, Horneff G. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2015;67(11): 1529–1535. doi: https://doi.org/10.1002/acr.22613
60. Simonini G, Druce K, Cimaz R, et al. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014;66(7):1073–1084. doi: https://doi.org/10.1002/acr.22214
61. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23. doi: https://doi.org/10.1002/art.20904
62. Renton WD, Jung J, Palestine AG. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database Syst Rev. 2022;10(10):CD013818. doi: https://doi.org/10.1002/14651858.CD013818.pub2
63. Li Y, Mao X, Tang X, Mao H. Efficacy and Safety of Anti-TNFα Therapy for Uveitis Associated with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. Rheumatol Ther. 2021;8(2):711–727. doi: https://doi.org/10.1007/s40744-021-00296-x
64. U.S. Food and Drug Administration. Highlights of Prescribing Information: HUMIRA (Adalimumab). FDA; 2023. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s423lbl.pdf. Accessed on May 03, 2025.
65. Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther. 2016;10: 2997–3003. doi: https://doi.org/10.2147/DDDT.S94188
66. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technol Assess. 2019;23(15): 1–140. doi: https://doi.org/10.3310/hta23150
67. Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis. Acta Ophthalmol. 2022;100(4):e994–e1001. doi: https://doi.org/10.1111/aos.15012
68. Choe S, Heo JW, Oh BL. Quiescence and Subsequent Anterior Chamber Inflammation in Adalimumab-treated Pediatric Noninfectious Uveitis. Korean J Ophthalmol. 2020;34(4):274–280. doi: https://doi.org/10.3341/kjo.2020.0005
69. Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003–1011. doi: https://doi.org/10.1136/annrheumdis-2017-212089
70. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637–1646. doi: https://doi.org/10.1056/NEJMoa1614160
71. Suhler EB, Adán A, Brézin AP, et al. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology. 2018;125(7): 1075–1087. doi: https://doi.org/10.1016/j.ophtha.2017.12.039
72. Ming S, Xie K, He H, et al. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther. 2018;12:2005–2016. doi: https://doi.org/10.2147/DDDT.S160431
73. Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575–1581. doi: https://doi.org/10.1016/j.ophtha.2012.02.018
74. Lazarević D, Ratković Janković M, et al. Long-term efficacy and safety of adalimumab in juvenile idiopathic arthritis (JIA) associated uveitis. Acta Med Medianae. 2021;60(3):30–36. doi: https://doi.org/10.5633/amm.2021.0304
75. Sheppard J, Joshi A, Betts KA, et al. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmol. 2017;135(6):511–518. doi: https://doi.org/10.1001/jamaophthalmol.2017.0603
76. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi: https://doi.org/10.1016/S0140-6736(16)31339-3
77. Ucan Gunduz G, Yalcinbayir O, Cekic S, et al. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab. J Ocul Pharmacol Ther. 2021;37(4):236–240. doi: https://doi.org/10.1089/jop.2020.0081
78. Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(3):339–344. doi: https://doi.org/10.1093/rheumatology/kem356
79. Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16. doi: https://doi.org/10.1186/1546-0096-11-16
80. Marino A, Real-Fernández F, Rovero P, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clin Rheumatol. 2018;37(5): 1407–1411. doi: https://doi.org/10.1007/s10067-018-4057-7
81. Brunelli JB, Silva CA, Pasoto SG, et al. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. Clin Rheumatol. 2020;39(2):515–521. doi: https://doi.org/10.1007/s10067-019-04798-6
82. Phatak S, Agrawal R, Pavesio C. Adalimumab: viable treatment option for pediatric refractory uveitis? Expert Rev Ophthalmol. 2014;9(3):175–184. doi: https://doi.org/10.1586/17469899.2014.903801
83. Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. Arthritis Care Res (Hoboken). 2019;71(4): 482–491. doi: https://doi.org/10.1002/acr.23610
84. Huard J, Mihailescu SD, Muraine M, et al. Effectiveness and Safety of Weekly Adalimumab for Non-Infectious Chronic Anterior Uveitis in Children. Ocul Immunol Inflamm. 2023;31(10):2039– 2049. doi: https://doi.org/10.1080/09273948.2023.2279682
85. Correll CK, Bullock DR, Cafferty RM, Vehe RK. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2018;37(2):549–553. doi: https://doi.org/10.1007/s10067-017-3890-4
86. Hughes DA, Culeddu G, Plumpton CO, et al. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. Ophthalmology. 2019;126(3): 415–424. doi: https://doi.org/10.1016/j.ophtha.2018.09.043
87. Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60(6):575–589. doi: https://doi.org/10.1016/j.survophthal.2015.06.004
88. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91(3):319–324. doi: https://doi.org/10.1136/bjo.2006.103721
89. Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005;33(5):461–468. doi: https://doi.org/10.1111/j.1442-9071.2005.01062.x
90. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(4):612–618. doi: https://doi.org/10.1002/acr.20404
91. Mase O, Qasem M, Beare N. Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis. BMJ Open Ophthalmol. 2023;8(1):e001303. doi: https://doi.org/10.1136/bmjophth-2023-001303
92. Jari M, Shiari R, Salehpour O, Rahmani K. Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):41. doi: https://doi.org/10.1186/s13023-020-1324-x
93. Liu W, Bai D, Kou L. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis. BMC Ophthalmol. 2023;23(1):240. doi: https://doi.org/10.1186/s12886-023-02987-1
94. Kreps EO, Epps SJ, Consejo A, et al. Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy. Eye (Lond). 2024;38(5):871–876. doi: https://doi.org/10.1038/s41433-023-02795-3
95. Miraldi Utz V, Bulas S, Lopper S, et al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. Pediatr Rheumatol Online J. 2019;17(1):79. doi: https://doi.org/10.1186/s12969-019-0383-9
96. Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144(6):844–849. doi: https://doi.org/10.1016/j.ajo.2007.08.018
97. Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40(1):74–79. doi: https://doi.org/10.3899/jrheum.120583
98. Cecchin V, Zannin ME, Ferrari D, et al. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2018;45(8):1167–1172. doi: https://doi.org/10.3899/jrheum.171006
99. Maccora I, Fusco E, Marrani E, et al. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatology (Oxford). 2021;60(2):568–587. doi: https://doi.org/10.1093/rheumatology/keaa595
100. Jin Y, Lu S, Lin Y, Mou X. The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis. Inflammopharmacology. 2022;30(4): 1363–1368. doi: https://doi.org/10.1007/s10787-022-01019-6
101. Okada K, Zhou Y, Hashida N, et al. The Efficacy of Golimumab Against Non-Infectious Uveitis: A PRISMA-Compliant Systematic Review and Meta-Analysis. Ocul Immunol Inflamm. 2023;31(5):1013–1023. doi: https://doi.org/10.1080/09273948.2022.2081584
102. William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2(4):231–233. doi: https://doi.org/10.1007/s12348-012-0081-y
103. Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin Exp Rheumatol. 2018;36(4):652–657.
104. Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab. Pediatr Rheumatol Online J. 2021;19(1):132. doi: https://doi.org/10.1186/s12969-021-00630-1
105. Tungsattayathitthan U, Tesavibul N, Choopong P, et al. Efficacy of golimumab in patients with refractory non-infectious panuveitis. Sci Rep. 2024;14(1):2179. doi: https://doi.org/10.1038/s41598-024-52526-1
106. Yazgan S, Celik U, Işık M, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017;37(1):139–145. doi: https://doi.org/10.1007/s10792-016-0239-y
107. Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22(2):90–95. doi: https://doi.org/10.3109/09273948.2013.844265
108. Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62(6):821–825. doi: https://doi.org/10.1002/acr.20115
109. Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(2):297–300. doi: https://doi.org/10.1007/s00417-010-1523-6
110. Gaggiano C, Rigante D, Tosi GM, et al. Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review. Clin Rheumatol. 2020;39(2):327–337. doi: https://doi.org/10.1007/s10067-019-04763-3
111. Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2015;42(4): 706–711. doi: https://doi.org/10.3899/jrheum.140410
112. Maccora I, Abu Rumeileh S, Curci F, et al. Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience. Front Pediatr. 2022;10:851453. doi: https://doi.org/10.3389/fped.2022.851453
113. Silpa-Archa S, Oray M, Preble JM, Foster CS. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400–e406. doi: https://doi.org/10.1111/aos.13015
114. Adán A, Moll-Udina A, Ramirez J, Llorenç V. Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report. Ocul Immunol Inflamm. 2021;29(1):6–8. doi: https://doi.org/10.1080/09273948.2019.1644350
115. Adán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627–2632. doi: https://doi.org/10.1007/s00417-013-2436-y
116. Maleki A, Manhapra A, Asgari S, et al. Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis. Ocul Immunol Inflamm. 2021;29(1):14–20. doi: https://doi.org/10.1080/09273948.2020.1817501
117. Dipasquale V, Atteritano M, Fresta J, et al. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases. J Clin Pharm Ther. 2019;44(3):482–485. doi: https://doi.org/10.1111/jcpt.12821
118. Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol. 2017;69(3):668–675. doi: https://doi.org/10.1002/art.39940
119. Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. Am J Ophthalmol. 2019;200:85–94. doi: https://doi.org/10.1016/j.ajo.2018.12.019
120. Quesada-Masachs E, Caballero CM. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis. J Rheumatol. 2017;44(2):260–261. doi: https://doi.org/10.3899/jrheum.160908
121. Karaca I, Uludag G, Matsumiya W, et al. Six-month outcomes of infliximab and tocilizumab therapy in non-infectious retinal vasculitis. Eye (Lond). 2023;37(11):2197–2203. doi: https://doi.org/10.1038/s41433-022-02315-9
122. Tappeiner C, Mesquida M, Adán A, et al. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2016;43(12): 2183–2188. doi: https://doi.org/10.3899/jrheum.160231
123. Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135–e141. doi: https://doi.org/10.1016/S2665-9913(20)30008-4
124. Ramanan AV, Dick AD, Jones AP, et al. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol. 2018;2:4. doi: https://doi.org/10.1186/s41927-018-0010-2
125. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47): 7359–7368. doi: https://doi.org/10.1038/sj.onc.1206939
126. Welzel T, Winskill C, Zhang N, et al. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology — what we know and what we do not know from randomized controlled trials. Pediatr Rheumatol Online J. 2021;19(1):46. doi: https://doi.org/10.1186/s12969-021-00514-4
127. Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50(8):1390–1394. doi: https://doi.org/10.1093/rheumatology/ker107
128. Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11(1):35–39. doi: https://doi.org/10.1016/j.autrev.2011.07.001
129. Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782–786. doi: https://doi.org/10.1136/bjophthalmol-2015-306790
130. Cao H, Ma X. Rituximab in the Treatment of Non-Infectious Uveitis: A Review. J Inflamm Res. 2024;17:6765–6780. doi: https://doi.org/10.2147/JIR.S477708
131. Ilizaliturri-Guerra O, Uriarte-Botello R, Pineda-Sic RÁ, et al. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus. Rheumatol Int. 2020;40(10): 1717–1724. doi: https://doi.org/10.1007/s00296-020-04668-4
132. Bauermann P, Heiligenhaus A, Heinz C. Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis. Ocul Immunol Inflamm. 2019;27(8):1232–1234. doi: https://doi.org/10.1080/09273948.2019.1605453
133. Miserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847–851. doi: https://doi.org/10.1007/s10067-019-04875-w
134. Eli Lilly and Company. A study of baricitinib (LY3009104) in participants from 2 years to less than 18 years old with active JIA-associated uveitis or chronic anterior antinuclear antibody-positive uveitis. Last Update Posted 2025-04-20. In: ClinicalTrials. gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04088409. Accessed on March 09, 2023.
135. Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021;22(1):689. doi: https://doi.org/10.1186/s13063-021-05651-5
136. Wen J, Hu H, Chen M, et al. Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review. J Immunol Res. 2021;2021:2324400. doi: https://doi.org/10.1155/2021/2324400
137. Proceedings of the 31st European Paediatric Rheumatology Congress: part 1. Pediatr Rheumatol. 2024;22(S2):82. doi: https://doi.org/10.1186/s12969-024-01004-z
138. Neves LM, Alves M. Juvenile Idiopathic Arthritis-Associated Uveitis: Evidence-Based Screening, Monitoring, and Treatment. In: Uveitis — Basics, Diagnosis, and Treatment [Working Title]. Feizi S, ed. 2023. doi: https://doi.org/10.5772/intechopen.110274
139. Horton S, Jones AP, Guly CM, et al. Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial. Am J Ophthalmol. 2019;207: 170–174. doi: https://doi.org/10.1016/j.ajo.2019.06.007
140. Acharya NR, Ramanan AV, Coyne AB, et al. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial. Lancet. 2025;405(10475):303–313. doi: https://doi.org/10.1016/S0140-6736(24)02468-1
141. Lerman MA, Lewen MD, Kempen JH, Mills MD. Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors. Am J Ophthalmol. 2015;160(1):193–200.e1. doi: https://doi.org/10.1016/j.ajo.2015.04.016
142. Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151(2):217–222. doi: https://doi.org/10.1016/j.ajo.2010.08.021
143. Al-Haddad C, BouGhannam A, Abdul Fattah M, et al. Patterns of uveitis in children according to age: comparison of visual outcomes and complications in a tertiary center. BMC Ophthalmol. 2019;19(1):137. doi: https://doi.org/10.1186/s12886-019-1139-5
144. Gregory AC 2nd, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120(1): 186–192. doi: https://doi.org/10.1016/j.ophtha.2012.07.052
145. Blum-Hareuveni T, Seguin-Greenstein S, Kramer M, et al. Risk Factors for the Development of Cataract in Children with Uveitis. Am J Ophthalmol. 2017;177:139–143. doi: https://doi.org/10.1016/j.ajo.2017.02.023
146. Oray M, Khachatryan N, Ebrahimiadib N, et al. Ocular morbidities of juvenile idiopathic arthritis-associated uveitis in adulthood: results from a tertiary center study. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1841–1849. doi: https://doi.org/10.1007/s00417-016-3340-z
147. Gautam Seth N, Yangzes S, Thattaruthody F, et al. Glaucoma Secondary to Uveitis in Children in a Tertiary Care Referral Center. Ocul Immunol Inflamm. 2019;27(3):456–464. doi: https://doi.org/10.1080/09273948.2017.1411517
148. Böhm MRR, Tappeiner C, Breitbach MA, et al. Ocular hypotony in patients with juvenile idiopathic arthritis-associated uveitis. Am J Ophthalmol. 2017;173:45–55. doi: https://doi.org/10.1016/j.ajo.2016.09.018
149. Loh AR, Acharya NR. Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol. 2010;150(4):534–542.e2. doi: https://doi.org/10.1016/j.ajo.2010.04.031
150. Sen HN, Drye LT, Goldstein DA, et al. Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. Ocul Immunol Inflamm. 2012;20(2):104–112. doi: https://doi.org/10.3109/09273948.2011.647228
151. Tran VT, Mermoud A, Herbort CP. Appraisal and management of ocular hypotony and glaucoma associated with uveitis. Int Ophthalmol Clin. 2000;40(2):175–203. doi: https://doi.org/10.1097/00004397-200004000-00014
152. Yangzes S, Seth NG, Singh R, et al. Long-term outcomes of cataract surgery in children with uveitis. Indian J Ophthalmol. 2019;67(4):490–495. doi: https://doi.org/10.4103/ijo.IJO_846_18
153. Kotaniemi K, Arkela-Kautiainen M, Haapasaari J, Leirisalo-Repo M. Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis. 2005;64(6): 871–874. doi: https://doi.org/10.1136/ard.2004.026955
154. Yakovlev AA, Gaidar EV, Belozerov KE, et al. Presence of uveitis as indicator of juvenile idiopathic arthritis severity: results of a retrospective cohort study. Pediatrician (St. Petersburg). 2023;14(2):37–47. (In Russ). doi: https://doi.org/10.17816/PED14237-47
155. Skarin A, Berthold E, Rauer O, Bengtsson-Stigmar E. Uveitis associated with juvenile arthritis: a continued cohort study 40 years after uveitis onset. Pediatr Rheumatol Online J. 2022;20(1):47. doi: https://doi.org/10.1186/s12969-022-00704-8
156. Skarin A, Elborgh R, Edlund E, Bengtsson-Stigmar E. Long-term follow-up of patients with uveitis associated with juvenile idiopathic arthritis: a cohort study. Ocul Immunol Inflamm. 2009;17(2): 104–108. doi: https://doi.org/10.1080/09273940802650398
Review
For citations:
Yakovlev A.A., Nikitina T.N., Kostik M.M. Juvenile Idiopathic Arthritis Associated Uveitis. Modern Therapy Approaches: Narrative Review. Current Pediatrics. 2025;24(3):162-177. (In Russ.) https://doi.org/10.15690/vsp.v24i3.2910
Views:
12
Email this article 
